Rivaroxaban plus standard therapy reduces thromboembolic events in HF, CAD patients - Cardiovascular Business

Rivaroxaban plus standard therapy reduces thromboembolic events in HF, CAD patients  Cardiovascular Business

Five milligrams of rivaroxaban per day added to a patient's standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient's ...